Phase 3

LenacapavirStudy of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

Sponsor:

Gilead Sciences

Code:

NCT07047716

Conditions

HIV Pre-exposure Prophylaxis

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Accepted

Interventions

Lenacapavir Injection

Lenacapavir Tablet

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by Gilead Sciences on 2026-06-22.